MISHC Data On ViV TAVR Presented During TCT 2024
Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) use is growing. Both balloon-expandable (BE) and self-expandable (SE) valves are used – each with unique features and outcomes. While both types of valves are effective, differences in their performance metrics, complications, and patient outcomes remain subjects of ongoing research. Long-term data comparing both BE vs SE is scarce.
Authors Omar Abdelhai, MD; Laith Alhuneafat, MD; Luai Madanat, MD; Ivan Hanson, MD; Brian Renard, MD; Amr Abbas, MD; and Pedro Villablanca, MD analyzed ViV TAVR patients from 2015 to 2022 MISHC data and linked Medicare claims to extend the analysis of long-term mortality beyond the 1-year follow-up.
In their ViV TAVR cohort, 1394 patients were analyzed comparing 683 BE and 711 SE valves.
The findings showed a significantly lower 30-day and 1-year mortality rate of BE valves compared to SE valves. There was no difference observed long-term at 5 years. A higher need for permanent pacemakers is observed with BE compared to SE. Further randomized controlled trials are needed to confirm the current findings.
You can view the entire presentation with your free or paid membership on tctmd.com. The presentation’s abstract is also published in a supplement of the Journal of the American College of Cardiology.